Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia

References

• Beasley C, Tollefson G, Tran P. Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111–123
   Google Scholar
• Tollefson G, Beasley C, Tran P. Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine ver-sus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorder: Results of an international collaborative trial. Am J Psychiatry 1997; 154:457–465
   Google Scholar
• Conley RR, Kelly DL: Management of treatment-resistant schizophrenia. Biol. Psychiatry 2001; 50:898–911
   PubMed Web of Science ®Google Scholar
• Love RC: Novel versus conventional antipsychotic drugs. Pharmacotherapy 1996; 16:6–10
   PubMedGoogle Scholar
• Conley RR, Tamminga CA, Richardson CM, Kelly DL: Treatment-resistant schizophrenic patients respond to clozap-ine after olanzapine non-response. Biol. Psychiatry 1999; 46: 73–77
   PubMed Web of Science ®Google Scholar
• Sheitman B, Lindgren J, Early J, Sved M: High-dose olanzapine for treatment-refractory schizophrenia. Am .1 Psychiatry 1997; 154: 1626
   Google Scholar
• Alao A, Armenta WA, Yolles IC: High-dose olanzap-Me therapy in schizophrenia. Ann Pharmacother 1999; 33:1228
   PubMed Web of Science ®Google Scholar
• Reich I: Use of high-dose olanzapine in refractory psychosis. Am J Psychiatry 1999; 156:661
   PubMed Web of Science ®Google Scholar
• Fanous A, Lindenmyer JP: Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J Clin Psy-chopharmacol 1999; 3:275–276
   Google Scholar
• Mountjoy CQ, Baldacchino AM, Stubbs JH: British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 1999; 156: 158––159
   Google Scholar
• Dursun SM, Gardner DM, Bird DC, Flinn J: Olanzapine for patients with treatment-resistant schizophrenia: A naturalis-tic case-series outcome study. Can J Psychiatry 1999; 44:701–704
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P. Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Liberman JA: Clozapine, olanzapine, risperidone and haloperidol in the treatment of pa-tients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 59:255–262
   Google Scholar
• Bronson BD, Lindenmayer J-P. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J Clin Psy-chopharmacol 2000; 20:382–384
   Google Scholar
• Citrome L, Volavka J: Optimal dosing of atypical antipsy-chotics in adults: A review of the current evidence. Hari/ Rev Psychiatry 2002; 10:280–291
   PubMed Web of Science ®Google Scholar
• DeRenzo EG, Conley RR, Love RC: Assessment of Capacity to give consent to research participation: State-of-the-art and beyond. J Health Care Law Policy 1998; 1(1):66–87
   PubMedGoogle Scholar
• Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT, Jr: The efficacy of high dose olanza-pine vs. clozapine in treatment-resistant schizophrenia: A double-blind crossover study. J Clin Psychopharmacol (in press).
   Google Scholar
• Gerlach .1: Improving outcome in schizophrenia: The poten-tial importance of eps and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14:47–57
   PubMedGoogle Scholar
• Kelly DL, Conley RR, Tamminga CA: Differential olanzapine plasma concentrations by sex in a fixed dose study. Schizophr Res 1999; 40(2): 101–104
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Birkett MA, Kiesler GM, Wood AJ: Lilly Re-sistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clin-ically eligible for treatment with clozapine. Biol Psychiatry 2001; 49:52–63
   Google Scholar
• Tracy II, Monaco C, Giovannetti T, Abraham G, Josiassen RC: Anticholinergicity and cognitive processing in chronic schizophrenia. Biol Psychiatry 2001; 56:1–22
   Google Scholar
• Meltzer HY, IvIcGurk SR: The effects of clozapine, risperi-done, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25:233–255
   PubMed Web of Science ®Google Scholar